Prevalence of Common Gynecological Conditions in the Middle East: Systematic Review and Meta-Analysis

Mira Mousa 1, Moamar Al-Jefout 2,3, Habiba Alsafar 4,5, Shona Kirtley 6, Cecilia M. Lindgren 7,8, Stacey A. Misser 9,10, Christian M. Becker 1†, Krina T. Zondervan 1,11† and Nilufer Rahmioglu 1,11*

† These authors have contributed equally to this work and share last authorship

**Introduction:** High prevalence of gynecological conditions in women of Middle Eastern origin is reported, likely due to regional risk factors and mediators. The objective of this systematic review and meta-analysis is to investigate the prevalence of polycystic ovary syndrome (PCOS), endometriosis, uterine fibroids, and adenomyosis in women of Middle Eastern origin.

**Methods:** MEDLINE, EMBASE, PsycINFO, Global Health, and Google Scholar databases were searched from database inception until 14 February 2021 to identify relevant studies. Peer-reviewed research articles that reported the prevalence of PCOS, endometriosis, uterine fibroids, and adenomyosis in the Middle Eastern population were written in English or Arabic. The primary outcome was the estimated pooled prevalence of PCOS, endometriosis, uterine fibroids, and adenomyosis in the Middle Eastern populations. The secondary outcome was to assess the evidence in the data for the presence of heterogeneity, by conducting subtype-pooled analysis of prevalence estimates of the conditions. Total weighted prevalence was calculated via Freeman–Tukey arcsine transformation and heterogeneity through the I² statistic. Quality control was performed using GRADE criteria.

**Results:** A total of 47 studies, 26 on PCOS, 12 on endometriosis, eight on uterine fibroids, and seven on adenomyosis, were included. The pooled prevalence of PCOS diagnosed according to the NIH criteria was 8.9% (95% CI: 6.5–11.7; prevalence range: 4.0–27.6%), with a higher prevalence from the Gulf Arab states (18.8%, 95%
INTRODUCTION

Polycystic ovary syndrome (PCOS), endometriosis, uterine fibroids, and adenomyosis are common benign gynecological conditions that affect women of reproductive age. They are often associated with dysfunctional uterine bleeding, pelvic pain, subfertility, psychological morbidity, and comorbid diseases (1–4). Genetic and environmental factors contribute to the risk of gynecological conditions, but none are currently specific enough to be clinically relevant. In addition, little is known regarding the reasons for the heterogeneity in symptomatology and contributing factors attributable to gynecological conditions in different populations of women, especially women of Middle Eastern origin. Table 1 summarizes the clinical epidemiology of PCOS, uterine fibroids, endometriosis, and adenomyosis, based on global statistics of mainly European ancestry populations.

The Middle East represents 6.8% of the world’s population (23 countries), yet it contributes <1% toward scientific research (28–31). Cross-population comparisons and regional differences, influenced by geographic, cultural, socioeconomic, genetic, and environmental factors, may alter health outcome measures associated with prevalence, symptomatology, diagnosis, and management of gynecological phenotypes. A high prevalence of gynecological conditions has been suggested in women of Middle Eastern origin, possibly due to consanguinity, obesity rates, environmental toxins from war exposure, and lack of awareness of reproductive health among adolescence (32–37).

The Middle East is a transcontinental region that consists of the Gulf Cooperative Council (GCC) Region (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates, Yemen), the Levant region (Cyprus, Iraq, Israel, Jordan, Lebanon, Palestine, Syria, Turkey), the North African region (Algeria, Egypt, Libya, Morocco, Somalia, Sudan, Tunisia), and the Persian region (Iran). The Middle Eastern populations have different degrees of genetic admixture, and higher prevalence of globally rare genetic variations with a highly conserved gene pool, due to consanguineous marriages and intercontinental migration (38–41). Consanguineous marriages account for 20–50% of marriages in the Arab ancestry Middle Eastern populations, resulting in higher frequency of recessive Mendelian diseases, large prevalence of deleterious genetic missense variants, and community-specific founder mutations (33, 42, 43). Nevertheless, the Middle East has a very diverse ancestral background, due to intercontinental migration between Africa, Asia, and Europe. Nine Middle Eastern countries have ranked highest in the global obesity statistics, with 70–75% of their populations being obese or overweight, with a 2-fold risk among women vs. men (36, 44–48). Physical inactivity and obesity rates in the region have been associated with gynecological diseases and menstrual disorders (49, 50). Additionally, exposure to war and environmental toxins may alter circulating hormone levels and the immune system of women (51).

This systematic review critically assesses the available evidence and quality of epidemiological studies that focus on the prevalence of common benign gynecological diseases in Middle Eastern populations, to inform public health policy and encourage studies into risk factors and prevention. The primary aim was to conduct a systematic review and meta-analysis of the prevalence of polycystic ovary syndrome, endometriosis, uterine fibroids, and adenomyosis in women of Middle Eastern origin. The secondary aim was to assess the evidence in the data for the presence of heterogeneity by conducting subtype-pooled analysis of prevalence estimates of the conditions.

METHODS

Search Strategy

This systematic review was reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (52, 53) and registered for inclusion in PROSPERO: CRD42019119804.
| Condition          | Prevalence | Symptoms                                                                 | Diagnosis                                     | Treatment                                      | Risk factors                                                                 | Annual patient cost estimate in European populations |
|--------------------|------------|---------------------------------------------------------------------------|-----------------------------------------------|------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------|
| Polycystic Ovary Syndrome | NIH criteria (∼5–9%)\(^a\), Rotterdam Criteria (∼10–20%)\(^b\),\(^c\) | - Hyperandrogenism\(^d\),\(^e\),\(^f\), - Menstrual irregularity\(^d\),\(^e\),\(^f\), - Oligo-anovulation\(^d\),\(^e\),\(^f\), - Hirsutism\(^d\),\(^e\),\(^f\), - Obesity\(^d\),\(^e\),\(^f\), - Dyslipidemia\(^d\),\(^e\),\(^f\), - Infertility\(^d\),\(^e\),\(^f\) | - Ultrasonography\(^d\),\(^e\),\(^f\), - Biochemical\(^d\),\(^e\),\(^f\), - Clinical evidence (NIH criteria and Rotterdam criteria)\(^d\),\(^e\),\(^f\) | - Medical treatment (suppressive hormonal therapy)\(^d\),\(^e\),\(^f\), - Ovarian drilling\(^d\),\(^e\),\(^f\) | - Early age of menarche\(^d\),\(^e\),\(^f\), - Ovulatory dysfunction\(^d\),\(^e\),\(^f\), - High body mass index\(^d\),\(^e\),\(^f\), - Insulin resistance\(^d\),\(^e\),\(^f\), - Metabolic syndrome features\(^d\),\(^e\),\(^f\), - Altered glucose homeostasis\(^d\),\(^e\),\(^f\), - Family history\(^d\),\(^e\),\(^f\), - Ethnicity\(^d\),\(^e\),\(^f\), - Early age of menarche\(^d\),\(^e\),\(^f\), - Short menstrual cycles\(^d\),\(^e\),\(^f\), - Increased menstrual flow\(^d\),\(^e\),\(^f\), - Low body mass index\(^d\),\(^e\),\(^f\), - Family history\(^d\),\(^e\),\(^f\), - Late menopause\(^d\),\(^e\),\(^f\) | €4,413 to €7,293\(^d\),\(^e\),\(^f\) |
| Endometriosis      | 5–10%\(^i\) | - Dysmenorrhea\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Dyspareunia\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Dyschezia\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Infertility\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Abnormal uterine bleeding\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Chronic pelvic pain\(^j\),\(^k\),\(^l\),\(^m\),\(^n\) | - Laparoscopy or laparotomy\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Magnetic resonance imaging\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Ultrasoundography\(^j\),\(^k\),\(^l\),\(^m\),\(^n\) | - Surgical removal of lesions\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Medical treatment (suppressive hormonal therapy)\(^j\),\(^k\),\(^l\),\(^m\),\(^n\) | - Early age of menarche\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Short menstrual cycles\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Increased menstrual flow\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Low body mass index\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Family history\(^j\),\(^k\),\(^l\),\(^m\),\(^n\), - Late menopause\(^j\),\(^k\),\(^l\),\(^m\),\(^n\) | €9,579\(^j\),\(^k\),\(^l\),\(^m\),\(^n\) |
| Adenomyosis        | 14–57%\(^s\) | - Menorrhagia\(^t\),\(^u\), - Dysmenorrhea\(^t\),\(^u\), - Endometrial polyps\(^t\),\(^u\), - Leiomyomata uteri\(^t\),\(^u\), - Chronic pelvic pain\(^t\),\(^u\) | - Transvaginal ultrasoundography\(^t\),\(^u\), - Magnetic resonance imaging\(^t\),\(^u\), - Hysterectomy\(^t\),\(^u\) | - Surgical extirpation\(^t\),\(^u\), - Medical treatment (Suppressive hormonal therapy)\(^t\),\(^u\) | - Increase in age\(^t\), - Number of births\(^t\), - Smoking\(^t\), - Previous uterine surgery\(^t\) | €6,719.9\(^t\),\(^u\) |
| Uterine fibroids   | 5–30%\(^x\) | - Abnormal uterine bleeding\(^y\),\(^z\), - Pelvic pain\(^y\),\(^z\), - Pelvic mass\(^y\),\(^z\), - Dyspareunia\(^y\),\(^z\), - Infertility\(^y\),\(^z\) | - Magnetic resonance imaging\(^y\),\(^z\), - Ultrasonography\(^y\),\(^z\), | - Medical treatment (suppressive hormonal therapy)\(^y\),\(^z\), - Uterine artery embolization\(^y\),\(^z\) | - Ethnicity\(^y\),\(^z\), - Early age of menarche\(^y\),\(^z\), - High body mass index\(^y\),\(^z\), - Parity\(^y\),\(^z\), - Smoking\(^y\),\(^z\) | €12,654 to €30,075\(^y\),\(^z\) |

\(^a\); \(^b\); \(^c\); \(^d\); \(^e\); \(^f\); \(^g\); \(^h\); \(^i\); \(^j\); \(^k\); \(^l\); \(^m\); \(^n\); \(^o\); \(^p\); \(^q\); \(^r\); \(^s\); \(^t\); \(^u\); \(^v\); \(^w\); \(^x\); \(^y\); \(^z\).
The electronic bibliographic databases, MEDLINE, EMBASE, PsycINFO, and GLOBAL HEALTH (through the OVID platform), and Google Scholar database, were searched from database inception until 14 February 2021. Search terms included a combination of free-text or controlled vocabulary terms (MeSH and EMTREE) for gynecological conditions including “Polycystic Ovary Syndrome,” “Endometriosis,” “Uterine Fibroids,” and “Adenomyosis.” We combined these with terms related to “Epidemiology” and “Prevalence” -related terms and terms for the “Middle East” -related countries. No other limits were applied to the search to obtain a comprehensive literature including the maximum possible number of studies. Details of the full search strategy used for the MEDLINE database are provided in Supplementary Text 1.

Eligibility Criteria and Selection of Studies

Peer-reviewed research articles that reported the prevalence of PCOS, endometriosis, uterine fibroids, and adenomyosis in women of Middle Eastern origin were included, in English and Arabic languages. The primary aim was to estimate the pooled prevalence estimate of PCOS, endometriosis, uterine fibroids, and adenomyosis in the Middle East, based on the following diagnostic criteria: NIH (54) and Rotterdam criteria (55) for PCOS; laparoscopic diagnosis for endometriosis; ultrasound sonography, MRI, and/or hysterectomy for adenomyosis; and ultrasound sonography, MRI, and/or hysterectomy for uterine fibroids. The secondary aim was to assess the evidence in the prevalence data for the presence of heterogeneity, in association to the following characteristics: ascertainment criteria (hospital-based/population-based), diagnostic criteria, age group of participants (adolescent/adult), country of origin (GCC region/Levant region/North Africa region/Persian region), type of study design (cross-sectional/cohort study), and availability of health insurance coverage.

The study outcomes to assess the pooled prevalence of PCOS were population-based study with the NIH criteria; population-based study with the Rotterdam criteria; hospital-based study with the Rotterdam criteria for any gynecological indication; and hospital-based study with the Rotterdam criteria for infertility investigation. For the pooled prevalence of endometriosis, distinction was made between population-based studies with a laparoscopic confirmation; hospital-based studies with a laparoscopic confirmation for any gynecological indication; and hospital-based studies with a laparoscopic confirmation for infertility investigation. The pooled prevalence of uterine fibroids and adenomyosis was divided into hospital-based studies with a hysterectomy or imaging diagnosis for any gynecological indication and hospital-based studies with a hysterectomy or imaging diagnosis for abnormal uterine bleeding investigation.

To reduce the risk of selection bias, methodological bias, and heterogeneity, studies were included in the meta-analysis when (i) the sample size involved >100 participants; (ii) diagnostic criteria were described; and (iii) prevalence estimates were reported. Reviews, editorials, and organizational guidelines were excluded to avoid bias toward more frequently cited publications. Case reports/series were excluded given that they use no control group to compare outcomes and have little statistical validity. Conference abstracts were excluded as there was no access to the full report and the studies were not peer-reviewed. To avoid over-representation of cases, when several studies on the same series of participants were published, only the report with the largest sample size was included in the meta-analysis.

Data Extraction

Retrieved articles were uploaded to EndNote and duplicates deleted. One reviewer (M.M.) reviewed the full library for relevance. A second reviewer (N.R.) reviewed the retrieved articles; inter-reviewer concordance was checked, and the third reviewer (K.Z.) adjudicated discordant results. A second round of review was conducted, and full texts were assessed for inclusion. Data was extracted into a standard form including study design, participant characteristics, ascertainment method, nationality, diagnostic criteria, confounding factors, prevalence estimates, and outcome measures. Missing data were collected where possible by emailing the corresponding author, or through statistical calculations reported in the Cochrane handbook for systematic reviews (56). All procedures conformed to the guidelines for systematic review and meta-analysis of observational studies in epidemiology: the Meta-analysis Of Observational Studies in Epidemiology Checklist (57).

Assessment of Risk of Bias

The quality control, assurance, and bias of the studies were assessed by two independent reviewers (M.M. and N.R.) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria (58, 59). The quality of evidence was monitored for each study based on risk of bias, imprecision, inconsistency, indirectness, and publication bias and scored on four levels of evidence: very low, low, moderate, and high. The studies and outcomes were rated down for clinical heterogeneity, methodological heterogeneity, unrepresentative control groups, insufficient diagnostic criteria for case definition, lack of adjustment to confounding variables, unclear selection criteria, sample size, confidence interval around effect estimate, and selection bias.

Data Synthesis

Statistical analyses were conducted using the metaprop function in R (R package: meta, Schwarzer 2008, Version 2.7.1). Meta-analysis was used to synthesize the pooling proportion estimates of the gynecological condition. The Freeman–Tukey double arc sine transformation was applied for normalizing and variance stabilizing of the proportion sampling distribution. This transformation also provided confidence limits of proportions between zero and one. Heterogeneity among studies was assessed via I² statistic. I² of 50% or above was designated significant heterogeneity and 30–49% moderate heterogeneity (60). The random-effect model of DerSimonian and Laird was used to estimate the pooled prevalence and its 95% CI, and I² heterogeneity was calculated for sensitivity analysis. Significant heterogeneity was explored by performing post-hoc subgroup meta-analyses to allow reliable conclusions to be drawn from analyses that involved subgroups. Forest plots demonstrate the
pooled prevalence estimates of the meta-analysis results. $P < 0.05$ was used as the threshold for statistical significance.

RESULTS

Study Selection and Characteristics

The search strategy across all databases retrieved 9,307 studies, 6,754 studies after duplicates were removed (Figure 1); 6,269 failed to meet the inclusion criteria based on abstract review. Following a full-text review of 485 studies, 438 were excluded because they did not meet the inclusion criteria. Of the 47 articles, 26 covered prevalence of PCOS, 12 endometriosis, 8 uterine fibroids, and 7 adenomyosis. There were 25 retrospective studies using electronic medical records and 22 cross-sectional studies; 29 were hospital-based and 18 population-based. There were 14 studies published from the GCC region, 14 studies from the Persian region, 14 studies from the Levant region, and 5 studies from the North African region. Detailed characteristics of the studies included are given in Table 2.

Of the 47 included studies, 27 received a GRADE score of “very low” and 20 studies received a GRADE score of “low” (Supplementary Table 1). The summary of the quality assessment for the studies included in the meta-analysis for each study outcome ($N = 11$; grouped based on multiple diagnostic criteria, sampling method, and definition of patient group prevalence estimation provided by each study, see Methods) also showed GRADE scores of “very low” and “low” (Table 3).

Polycystic Ovary Syndrome

Twenty-six studies reported prevalence estimates of PCOS, with eight reporting NIH criteria-based prevalence, 15 Rotterdam criteria-based prevalence, and three studies utilizing both the NIH and Rotterdam criteria (Figure 2). The population-based pooled prevalence of PCOS according to NIH criteria was 8.9% (95% CI: 6.5–11.7; range: 3.0–27.6%) (Figure 2A). Due to high heterogeneity ($I^2 = 94.0\%$) observed among the studies, results are presented from a random-effects model. Pooled prevalence of PCOS in the Levant region and Persian region was estimated...
TABLE 2 | Characteristics of the 47 studies included in the meta-analysis.

| References | Country | Study period | Study design | Participant ascertainment | Sample size | Age Mean ± Sd (Range) | Gynecological condition | Diagnostic method/criteria |
|------------|---------|--------------|--------------|---------------------------|-------------|-----------------------|-------------------------|-------------------------|
| (61) Egypt | 1998–2005 | Retrospective | Electronic records screened for women attending the endoscopy unit at the obstetrics and gynecology department in a University hospital | 2,493 | 26.8 ± 5.3 (Not reported) | Endometriosis | Laparoscopy |
| (62) Egypt | 2012–2014 | Cross-sectional | Adolescent girls with severe dysmenorrhea | 220 | 15.2 ± 3.53 (Not reported) | Endometriosis | Laparoscopy |
| (63) Egypt | 2011–2012 | Cross-sectional | Infertile women visiting a specialized infertility clinic | 3,900 | 27.9 ± 4.9 (Not reported) | PCOS | Rotterdam criteria |
| (64) Egypt | 2010–2011 | Cross-sectional | Infertile women visiting an outpatient clinic in a University hospital | 830 | 26.8 ± 5.4 (18.0–37.0) | PCOS | Rotterdam criteria |
| (65) Egypt | 2001–2010 | Retrospective | Electronic records screened for the investigation of infertility in a University hospital | 4,103 | 27.6 ± 4.8 (Not reported) | Endometriosis | Laparoscopy; Rotterdam criteria |
| (66) Iran | 2012–2013 | Cross-sectional study | Women referred for a laparoscopy due to unexplained infertility | 383 | 30.9 ± 5.3 (Not reported) | Endometriosis | Laparoscopy |
| (67) Iran | 2001–2003 | Retrospective | Electronic records screened for women presenting with hirsutism to the dermatology clinic in a University hospital | 790 | 25.9 ± 5.7 (10.0–45.0) | PCOS | Rotterdam criteria |
| (68) Iran | 2011–2013 | Retrospective | Electronic records screened for women who underwent laparoscopy for the investigation of infertility in a hospital | 1,282 | 32.4 ± 4.9 (16.0–46.0) | Endometriosis | Laparoscopy |
| (69) Iran | 2009 | Cross-sectional study | Female high school students | 1,850 | 17.2 ± 0.70 (17.0–18.0) | PCOS | NIH Criteria |
| (70) Iran | Not reported | Cross-sectional study | Female high school students | 1,549 | 17.3 ± 0.9 (16.0–20.0) | PCOS | Rotterdam criteria |
| (71) Iran | Not reported | Cross-sectional study | Female high school students | 1,000 | 16.0 ± 1.9 (16.0–20.0) | PCOS | NIH criteria |
| (72) Iran | 2001–2011 | Retrospective | Women attending a hospital for a hysterectomy | 191 | 51.6 ± 12.5 (23.0–85.0) | Adenomyosis | Hysterectomy |
| (73) Iran | 2007–2008 | Retrospective | Women attending a hospital for a hysterectomy | 100 | 48.6 ± 7.8 (21.0–75.0) | Adenomyosis; uterine fibroids | Hysterectomy |
| (74) Iran | 2009 | Cross-sectional study | Mandatory pre-marriage screening clinic | 820 | 29.1 ± 7.6 (Not reported) | PCOS | Rotterdam/NH criteria |
| (75) Iran | Not reported | Cross-sectional study | Multi-stage random sampling of random household lists of premenopausal women available in the health department | 602 | 33.2 ± 3.6 (18.0–45.0) | PCOS | Rotterdam/NH criteria |
| (76) Iran | 2005–2006 | Cross-sectional study | Multistage random sampling of high school students in Tehran | 1,430 | 15.8 ± 1.1 (15.0–18.0) | PCOS | Rotterdam criteria |
| (77) Iran | Not reported | Cross-Sectional Study | Random sampling method of participants selected from the Tehran lipid and glucose study | 1,002 | 29.2 ± 8.7 (18.0–45.0) | PCOS | NIH criteria |
| (78) Iran | Not reported | Cross-sectional study | Random household lists of premenopausal women available in the health department | 929 | 34.4 ± 7.6 (18.0–45.0) | PCOS | Rotterdam/NH criteria |
| (79) Iraq | 2020 | Cross-sectional study | Cluster sampling method from young adolescent girls at high schools | 900 | 15.96 ± 0.91 (14.0–18.0) | PCOS | NIH criteria |
| References | Country       | Study period | Study design     | Participant ascertainment                                                                 | Sample size | Age Mean ± Sd (Range)       | Gynecological condition     | Diagnostic method/criteria       |
|------------|---------------|--------------|------------------|-------------------------------------------------------------------------------------------|-------------|----------------------------|------------------------------|----------------------------------|
| (80)       | Iraq          | 2017         | Cross-sectional  | Women attending an infertility center in a hospital                                         | 100         | Not reported (21.0–44.0)   | PCOS                         | Rotterdam criteria              |
| (81)       | Iraq          | 2007–2008    | Retrospective    | Women attending a hospital for a hysterectomy                                             | 391         | 46.6 ± 4.2 (40.0–49.0)     | Adenomyosis; uterine fibroids | Hysterectomy                    |
| (82)       | Israel        | 1998–2015    | Retrospective    | Performed from the Maccabi healthcare service database                                      | 570,781     | 40.4 ± 8.0 (15.0–55.0)     | Endometriosis                | Laparoscopy                     |
| (83)       | Israel        | Not reported | Cross-sectional  | Post-menopausal women attending an out-patient clinic                                      | 104         | 56.3 ± 5.5 (47.0–64.0)     | PCOS                         | Rotterdam criteria              |
| (84)       | Jordan        | 2015         | Cross-sectional  | Self-administered questionnaire from random women selected at universities, schools, and shopping centers | 1,772       | 27.9 ± 5.7 (15.0–45.0)     | Endometriosis                | Laparoscopy                     |
| (85)       | Jordan        | 2008–2009    | Retrospective    | Women attending hospital for a hysterectomy                                               | 148         | 46.6 ± 5.7 (35.0–76.0)     | Adenomyosis; uterine fibroids | Hysterectomy                    |
| (86)       | Lebanon       | 1979–1981    | Retrospective    | Women who have undergone gynecological laparoscopy in a University hospital               | 882         | 31.5 ± 4.7 (17.0–52.0)     | Endometriosis                | Laparoscopy                     |
| (87)       | Lebanon       | Not reported | Retrospective    | Electronic records screened for women presenting with hirsutism to the endocrinology clinic | 146         | 22.0 ± 5.1 (Not reported)  | PCOS                         | Rotterdam criteria              |
| (88)       | Middle Eastern women in Sweden | 1990–2004 | Retrospective | The total population register, Swedish national hospital discharge register, and the national cause of death register (only middle eastern population was extracted) | 46,384 | Not reported (20.0–41.0) | Endometriosis | Laparoscopy |
| (89)       | Oman          | 2006–2010    | Retrospective    | Electronic records screened for premenopausal women presenting to gynecology outpatients in a University hospital | 3,644 | 24.2 ± 5.4 (15.0–45.0) | PCOS | Rotterdam criteria |
| (90)       | Oman          | 2007–2009    | Retrospective    | Women attending a hospital                                                                | 3,560       | Not reported (18.0–45.0)   | PCOS                         | Rotterdam criteria              |
| (91)       | Palestine     | 2011–2012    | Cross-sectional  | Random sample of students selected from An-Najah National University                       | 137         | 20.2 ± 1.40 (18.0–24.0)   | PCOS                         | NIH criteria                   |
| (92)       | Qatar         | Not reported | Cross-sectional  | Eligible participants from the Qatar Biobank                                              | 720         | 27.2 ± 2.88 (18.0–40.0)   | PCOS                         | NIH criteria                   |
| (93)       | Qatar         | 2011         | Cross-sectional  | Random sample of students from University                                                 | 120         | 21.0 ± 2.00 (18.0–30.0)   | PCOS                         | NIH criteria                   |
| (94)       | Saudi Arabia  | 1990–2002    | Retrospective    | Women attending a hospital for an ultrasound                                              | 1,111       | Not reported (15.0–79.0)   | Uterine fibroids             | Ultrasound                      |
| (95)       | Saudi Arabia  | 1996–1999    | Retrospective    | Women attending a hospital for a hysterectomy                                             | 108         | 49.8 ± 8.2 Not reported    | Uterine fibroids             | Hysterectomy                    |
| (96)       | Saudi Arabia  | 2000–2005    | Retrospective    | Women presenting with hirsutism to the endocrinology clinic in a University hospital      | 101         | 24.5 ± 6.6 (Not reported)  | PCOS                         | Rotterdam criteria              |
| (97)       | Saudi Arabia  | 2008–2013    | Retrospective    | Women who have undergone gynecological laparoscopy in a University hospital               | 190         | 33.8 ± 8.9 (Not reported)  | Endometriosis | Laparoscopy |
TABLE 2 | Continued

| References | Country       | Study period | Study design    | Participant ascertainment                                                                 | Sample size | Age Mean ± Sd (Range) | Gynecological condition | Diagnostic method/criteria |
|------------|---------------|--------------|----------------|-------------------------------------------------------------------------------------------|-------------|-----------------------|-------------------------|----------------------------|
| (98)       | Saudi Arabia  | 1990–2002    | Retrospective  | Women attending a hospital for a hysterectomy                                             | 251         | Not reported (18.0–60.0) | Uterine fibroids        | Hysterectomy               |
| (99)       | Turkey        | 2017–2019    | Retrospective  | Women attending infertility polyclinics                                                   | 3,033       | Not reported          | PCOS                    | Rotterdam criteria        |
| (100)      | Turkey        | 2009–2014    | Retrospective  | Women attending a hospital for a hysterectomy due to heavy bleeding                      | 129         | 49.0 ± 3.1            | Adenomyosis; uterine fibroids | Hysterectomy               |
| (101)      | Turkey        | 2003–2004    | Retrospective  | Women attending a hospital for a hysterectomy                                             | 298         | 50.0 ± 4.1            | Adenomyosis             | Hysterectomy               |
| (102)      | UAE           | 2016         | Cross-sectional study | Self-administered questionnaire from random women selected at a University | 3,572       | 24.9 ± 5.2            | Endometriosis           | Laparoscopy               |
| (103)      | UAE           | 1990–1994    | Retrospective  | Women attending an endocrine clinic for hirsutism                                        | 102         | 22.0 ± 5.1            | PCOS                    | Rotterdam criteria        |
| (104)      | UAE           | 2012–2015    | Retrospective  | Women who have undergone gynecological laparoscopy in an endometriosis clinic in a hospital | 5,881       | 32.1 ± 5.8            | Endometriosis           | Laparoscopy               |
| (105)      | UAE           | 2012         | Cross-sectional study | Random sample of students selected from Ras Al Khaimah Medical University | 250         | 19.7 ± 1.88           | PCOS                    | NIH Criteria              |
| (106)      | Yemen         | 2006–2012    | Retrospective  | Women attending a hospital for a hysterectomy                                             | 2,544       | 47.6 ± 5.0            | Adenomyosis; uterine fibroids | Hysterectomy               |

NIH, National Institute of Health; PCOS, polycystic ovary syndrome.
| Study outcome                                      | No. of studies | Grade score | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Uplifting factors                     |
|---------------------------------------------------|----------------|-------------|--------------|--------------|---------------|--------------|-------------|------------------|---------------------------------------|
| **Polycystic ovary syndrome**                     |                |             |              |              |               |              |             |                  |                                       |
| Population-based study: NIH criteria              | 12             | Very low    | 2; non-RCT   | −1; Six studies with high risk of bias (unrepresentative sample of population; did not specify recruitment strategy) | −1; high heterogeneity due to inconsistency in recruitment strategy and target population | 0; all studies demonstrated directness of evidence | −1; two studies with imprecision (sample size not statistically significant) | 0; none | 2; Four studies with representative sample and similar direction of effect; four studies with large sample size |
| Population-based study: Rotterdam criteria       | 6              | Low         | 2; non-RCT   | 0; five studies with low risk of bias (all samples were selected from the same country) | −1; high heterogeneity due to inconsistency in recruitment strategy and target population | 0; all studies demonstrated directness of evidence | 0; all studies demonstrated precision in sample | 0; None | 1; three studies with representative sample and similar direction of effect; two studies with large sample size |
| Hospital-based study: any indication via Rotterdam criteria | 3           | Low         | 2; non-RCT   | 0; two studies with low risk of bias (retrospective studies that identifies prevalence within a defined group) | 0; no heterogeneity | 0; all studies demonstrated directness of evidence | −1; one study with imprecision (sample size not statistically significant) | 0; none | 1; two studies with large sample size, adequate disease ascertainment |
| Hospital-based study: infertility via Rotterdam criteria | 5           | Very low    | 2; non-RCT   | −1; three studies with high risk of bias (unrepresentative of control group and whole study population) | −1; high heterogeneity due to inconsistency in recruitment strategy and target population with inadequate sample ascertainment | 0; all studies demonstrated directness of evidence | 0; all studies demonstrated precision in sample | 0; none | 1; three studies with large sample size |
| **Endometriosis**                                |                |             |              |              |               |              |             |                  |                                       |
| Population-based study                            | 4              | Very low    | 2; non-RCT   | −1; two studies with high risk of bias (unrepresentative of control group or whole population; self-reported outcomes) | −1; high heterogeneity due to inconsistency in recruitment strategy and target population | 0; all studies demonstrated directness of evidence | −1; two studies with imprecision (recruited a younger sample group) | 0; none | 2; two studies with representative sample and similar direction of effect |
| Hospital-based study: any indication              | 4              | Very low    | 2; non-RCT   | 0; two studies with low risk of bias (retrospective studies that identifies prevalence within a defined group) | −1; high heterogeneity due to inconsistency in recruitment strategy and target population | −1; two studies demonstrated indirectness of evidence (did not report total sample size in manuscript) | −1; one study with imprecision (sample size not statistically significant) | 0; none | 1; two studies with large sample size, adequate disease ascertainment |
| Hospital-based study: infertility                 | 3              | Low         | 2; non-RCT   | 0; two studies with low risk of bias (unrepresentative of population) | −1; high heterogeneity due to inconsistency in recruitment strategy and target population | 0; all studies demonstrated directness of evidence | 0; all studies demonstrated precision in sample | 0; None | 1; two studies with large sample size, adequate disease ascertainment |
| **Uterine fibroids**                             |                |             |              |              |               |              |             |                  |                                       |
| Hospital-based study: any indication              | 6              | Low         | 2; non-RCT   | −1; five studies with high risk of bias (unrepresentative of control group and whole study population; retrospective studies) | −1; high heterogeneity due to inconsistency in recruitment strategy and target population | 0; all studies demonstrated directness of evidence | 0; all studies demonstrated precision in sample | 0; none | 2; two studies reported adequate disease ascertainment and high sample size |

(Continued)
at the lower range of the scale with 6.3% (95% CI: 4.4–8.6; range: 6.1–7.3%) (6, 91) and 6.7% (95% CI: 4.6–9.1; range: 3.0–11.3%) (69, 71, 74, 75, 77–79), respectively, whereas prevalence estimates in the Gulf Arab states were 18.8% (95% CI: 9.5–30.3; range: 12.0–27.6%) (92, 93, 105). The population-based pooled prevalence according to the Rotterdam criteria was 11.9% (95% CI: 7.1–17.6; range: 3.4–19.9%) but only included studies from Iran and Turkey, from the Persian and Levant regions (Figure 2B). Among post-menarche adolescent women (<18 years of age), the pooled prevalence was 5.6% (95% CI: 1.8–11.3; range: 3.0–8.3%) (76, 107), whereas among pre-menopausal adult women (>18 years of age), it was much higher, at 15.6% (95% CI: 13.6–17.7; range: 14.1–19.9%) (6, 74, 75, 78).

The hospital-based prevalence studies of PCOS were categorized into (i) women presenting to obstetrics and gynecology clinics with any indication: 6.8% (95% CI: 6.3–7.4; range: 6.7–7.0%) (Figure 2C) and (ii) infertile women: 23.4% (95% CI: 15.6–32.2; range: 10.4–37.4) (Figure 2D). The three hospital-based studies estimated lower prevalence rates, but one of the studies only recruited post-menopausal women (6.7%, 95% CI: 3.3–13.2) (83), and the other two analyzed medical records retrospectively (7.0%, 95% CI: 6.2–7.9 and 7.0%, 95% CI: 6.1–7.8) (89, 90). The high heterogeneity ($I^2 = 99\%$) that was observed for the infertile pooled prevalence estimate is likely due to the fact that two of the studies were recruiting participants from a specialized infertility clinic (10.4%, 95% CI: 9.5–11.44 and 23.4%, 95% CI: 21.9–24.9) (63, 99), whereas the other three studies were recruiting infertile women that were visiting the obstetrics and gynecology department in a University hospital (18.5%, 95% CI: 17.3–19.7; 37.4%, 95% CI: 34.1–40.8 and 33.0%, 95% CI: 23.9–43.1) (64, 65, 80). Hence, the former group may be women with severe PCOS phenotype that require specialized fertility services and assistive reproductive technology, whereas the latter group may be women who require fertility medical treatment. Since hyperandrogenism is part of the Rotterdam criteria, and hirsutism is caused by increased androgenicity in the pilosebaceous gland, the pooled prevalence within the hirsute patients diagnosed with PCOS was very large, at 70.2% (95% CI: 57.7–81.7; range: 62.5–82.1%; $I^2 = 96\%$) (67, 87, 96, 103, 108).

**Endometriosis**

Twelve studies reported prevalence estimates of endometriosis diagnosed via laparoscopic surgical visualization, and four out of these 12 reported additional histological confirmation (Figure 3). The pooled prevalence for surgically confirmed endometriosis in population studies, which were validated through surgical records, was estimated at 1.2% (95% CI: 0.9–1.6, range: 0.8–2.4%) (Figure 3A). Two of these studies retrospectively extracted data from large-scale population-based databases in Israel (82) and Middle Eastern women living in Sweden (88). Two further cross-sectional studies in Jordan (84) and the U.A.E. (102) assessed women attending universities who could be affected but given the younger age may not have undergone laparoscopic intervention or sought medical help.

The hospital-based prevalence for studies of endometriosis among women undergoing laparoscopy for unspecified indication was 12.9% (95% CI: 4.1–25.4, range: 4.2–21.0%).

---

**TABLE 3 | Continued**

| Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Publica tion bias |
|--------------|-------------|---------------|--------------|-------------|------------------|
| Study outcome | No. of Grade score | | | | |
| Hospital-based study: abnormal uterine bleeding | Very low | Low | Very low | | |
| Hospital-based study: any indication | Very low | Low | Very low | | |

---

**FIGURE**

The hospital-based prevalence for studies of endometriosis among women undergoing laparoscopy for unspecified indication was 12.9% (95% CI: 4.1–25.4, range: 4.2–21.0%).
FIGURE 2 | Forest plot of the pooled prevalence estimates of PCOS: (A) population-based study based on the NIH criteria, (B) population-based study based on the Rotterdam criteria, (C) hospital-based study (obstetrics and gynecology department) based on the Rotterdam criteria, and (D) hospital-based study (presenting with infertility) based on the Rotterdam criteria.
However, differences in prevalence estimates were observed based on the availability of healthcare insurance coverage (Figure 3B). Despite the importance of healthcare insurance coverage to provide cost-effective, quality healthcare services, most of the region did not provide or implement insurance coverage for the citizens and residents until the World Health Assembly passed a resolution in 2005 (30, 109, 110). Articles from countries that were published before 2006 had limited health care insurance coverage with a pooled prevalence estimate of 19.6% (95% CI: 17.5–21.7; range: 18.8–21.0%) (61, 86), as opposed to a prevalence estimate of 6.9% (95% CI: 1.7–15.2%; range: 4.2–11.0%) (84, 102) for articles in countries published after the implementation of healthcare insurance coverage.

**FIGURE 3** | Forest plot of the pooled prevalence estimate of surgically confirmed endometriosis: (A) population-based study, (B) hospital-based study (undergoing laparoscopy for any reason), (C) hospital-based study (presenting with infertility), and (D) hospital-based study (presenting with pelvic pain).
2007 with highly available private healthcare insurance coverage. Wider healthcare insurance coverage may reflect the lower prevalence estimate for surgically confirmed endometriosis, due to more accessibility to surgical procedures (111). The pooled hospital-based prevalence of endometriosis among infertile women undergoing laparoscopy was higher than for any indication, at 24.9% (95% CI: 5.2–53.0), although study estimates varied widely (range: 5.7–50.3%) (65, 66, 68) (Figure 3C). One large prospective study in Egypt (N = 2,493) showed that infertility is the primary reason for laparoscopic surgery in 80.9% of surgeries, followed by chronic pelvic pain in 12.2% and other indications in 14.5%. Endometriosis was diagnosed in 38.8, 46.6, and 14.5% of these three groups, respectively (61). This suggests that patients are more likely to seek medical treatment due to infertility compared to pelvic pain or other indications, which may be due to limited access of unmarried women to gynecology clinics. The hospital-based prevalence of endometriosis among women undergoing laparoscopy for pelvic pain was only estimated in a single study, at 12.2% (95% CI: 8.2–17.3) (62) (Figure 3D). The prevalence of endometriosis is likely overestimated among women undergoing surgery for pain symptoms and/or infertility; hence, there is an inherent selection bias in these groups compared to the general population.

Endometriosis was staged laparoscopically according to the four stages of the American Society of Reproductive Medicine (ASRM) staging system in 4 out of 12 studies (61, 68, 104, 112). The laparoscopic presentation of stage I/II vs. stage III/IV endometriosis was noted in one study (66). The endometriosis stage was not mentioned in eight of the 12 studies. Pooled prevalence of endometriosis for patients undergoing laparoscopy for any indication, according to the ASRM staging system, was 21.7% (95% CI: 13.8–30.8, \( I^2 = 92.8\% \)) for stage I, 34.1% (95% CI: 25.3–43.4, \( I^2 = 73.7\% \)) for stage II, 26.1% (95% CI: 14.9–39.1, \( I^2 = 96.1\% \)) for stage III, and 15.3% (95% CI: 8.03–24.3) for stage IV. Only one study reported the prevalence of endometriosis, according to ASRM criteria, for patients undergoing laparoscopy for infertility: 15.3% (52/341) for stage I, 24.9% (85/341) for stage II, 32.5% (111/341) for stage III, and 24.6% (84/341) for stage IV (68), and one study for patients undergoing laparoscopy for pelvic pain: 44.4% (12/27) for stage I, 25.9% (7/27) for stage II, and 29.6% (8/27) for stage III (62). Stage was not correlated with pelvic pain or infertility, as reported in previous studies (113).

Uterine Fibroids

Eight hospital-based studies estimated the prevalence of uterine fibroids by retrospectively screening electronic medical records of women (Figure 4). Seven studies utilized hysterectomy as the diagnostic tool, and only one study utilized imaging and clinical assessment to diagnose uterine fibroids. The pooled hospital-based prevalence of uterine fibroids in women undergoing hysterectomy or ultrasound was 30.6% (95% CI: 24.9–36.6; range: 18.5–42.6%) for any indication (Figure 4A). The pooled hospital-based prevalence of uterine fibroids in women undergoing hysterectomy for abnormal uterine bleeding was 57.1% (95% CI: 45.5–68.4; range: 51.0–62.7%) (Figure 4B), while the prevalence of uterine fibroids diagnosed by ultrasound was 21.2% (95% CI: 18.8–23.7).

Adenomyosis

Five hospital-based studies reported the prevalence of adenomyosis by retrospectively screening electronic medical records of women attending a hospital for a hysterectomy (Figure 5). The hospital-based prevalence of adenomyosis in women undergoing hysterectomy for any indication was 30.8% (95% CI: 27.1–34.6, range: 25.5–37.7%) (Figure 5A) and 47.2% (95% CI: 40.7–53.7, range: 45.7–49.0%) for heavy menstrual bleeding (Figure 5B). Women diagnosed with adenomyosis often have other associated gynecological diseases, such as endometriosis or uterine fibroids, which complicates differential diagnosis and attribution of symptoms. In addition, no study provided an imaging-based diagnosis that could provide a more representative population-based estimate. While the gold standard for diagnosis has been histopathologic examination of the uterus after hysterectomy, the prevalence may be underestimated due to missed adenomyosis from cases that are not managed by hysterectomy (114).

DISCUSSION

Main Findings

We conducted the first systematic review and meta-analysis of pooled prevalence of PCOS, endometriosis, uterine fibroids, and adenomyosis in women from the Middle East, a region representing 6.8% of the world’s population but underserved in clinical science (28–31). Much of the scientific research featured poorly designed studies and methodological and statistical heterogeneity. The region lacks reliable, population-based data on the major causes of women's health diseases due to limited reporting regulations and lack of national registries (29, 31).

Our findings indicate that the population-based prevalence of PCOS according to NIH and Rotterdam diagnostic criteria in the Middle Eastern populations is estimated at 8.9% (95% CI: 6.5–11.7) and 11.9% (95% CI: 7.1–17.6), respectively, which are similar to the estimated global prevalence (5–9% and 10–20%, respectively) (2). However, among women from the Gulf Region, there was a substantially higher prevalence of PCOS (18.8%; 95% CI: 9.5–30.3) in comparison to women from the Levant (6.3%; 95% CI: 4.4–8.6) and Persian Region (6.7%; 95% CI: 4.6–9.1), based on the NIH criteria. Obesity rates in the Arab Gulf countries exceed those of the remaining Middle Eastern region, with a gender disparity among women, for all age groups (115), where the prevalence of overweight and obesity among adults is 35–48 and 24–40%, respectively (116). Obesity is a common clinical feature in women affected by PCOS, due to its association to the onset of oligomenorrhea and hyperandrogenism (117). Comorbid conditions of PCOS, such as hyperinsulinemia, type 2 diabetes mellitus, cardiovascular disease, and dyslipidemia, have also been reported to have the highest prevalence in the Arab Gulf countries (118–120). Hence, it is likely that the prevalence differences of PCOS between the regions are at least in part due to the pathogenetic role on obesity in the subsequent development of PCOS (117). Analysis of a genome-wide association study (GWAS) on PCOS demonstrated that the relative severity of the PCOS phenotypes, in particular severe hirsute-hyperandrogenism, may
result from different combinations of SNPs more commonly present in women of Middle Eastern origin. This may be a basis for the higher prevalence of PCOS that is dominated by obesity, high blood pressure, diabetes mellitus, and hirsutism (121, 122). Genetic influences in populations of diverse origin are important to study alongside environmental influences, to understand the effect of their interaction in causing different PCOS phenotypes (123). Additionally, high heterogeneity was reported due to variability of age group of the participants among studies, where post-menarche adolescent women and post-menopausal women reported a lower prevalence of PCOS compared to pre-menopausal adult women. Adolescents with PCOS manifest similar clinical, metabolic, and endocrine features to adult women (124); hence, the significant difference could be
attributed to delayed diagnosis of the condition among young, single women who are unable to access reproductive health care due the hegemony of traditions that may prevent them from discussing their symptoms and seeking care.

Prevalence for surgically confirmed endometriosis (12.9% among women undergoing laparoscopy for any indication; 24.4% among infertile women; 12.2% among women hospitalized for pelvic pain; 1.28% in a population-based setting) was similar to European ancestry populations (5–10% among women undergoing laparoscopy; 5–50% among infertile women; 5–21% among women hospitalized for pelvic pain; 2–43% among asymptomatic women seeking tubal ligation) (4, 17, 125). However, the reliance on surgical confirmation of endometriosis, access to clinics that is mostly limited to married women, and consequent selection biases affect these estimates, as is demonstrated by the heterogeneity estimates in our meta-analyses. As the main presenting symptomatology of endometriosis and mode of diagnosis are both influenced by psychosocial factors, women of different cultural backgrounds may present with different clinical phenotypes. Further epidemiological studies must be conducted among women of different populations, to explore the diagnostic pathways for women with endometriosis and be able to obtain an accurate prevalence estimate for the population. In addition, given that endometriosis has an estimated heritability of ~50% and the region has an estimated consanguinity rate of 20–50%, increased prevalence of endometriosis may be mediated by numerous deleterious recessive alleles due to increased homozygosity levels (126–128). Most GWAS datasets have been generated from women of European ancestry, with only two in women of East Asian ancestry. It is important to define the extent of the effects of specific risk alleles in different ethnic groups and conduct trans-ethnic mapping to restrict signal to causal variants of endometriosis (129–131).

The hospital-based pooled prevalence of uterine fibroids for women was estimated at 28.2% (95% CI: 20.4–36.7), vs. 57.1% (95% CI: 45.5–68.4) among women with heavy menstrual bleeding, which are on the high end of the estimated global prevalence 5–30% (3) and 37–59% (132), respectively. Detection bias may explain the overestimation of uterine fibroid prevalence as nearly all studies were from women presenting for hysterectomy. Considering the consistently observed greater risk of uterine fibroids among black women, it is important to conduct further more robust epidemiological and genetic studies in women of Middle Eastern origin, to investigate whether they also exhibit a higher prevalence and whether this is associated with certain risk factors (3, 132, 133). The hospital-based prevalence of adenomyosis for women undergoing hysterectomy was high (any indication: 31.7% [95% CI: 20.6–43.9]; for heavy menstrual bleeding: 47.2% [95% CI: 40.7–53.7]), but within the range previously reported for studies assessing prevalence at hysterectomy (14–57%) (21). The restriction of hospital-based studies to women undergoing hysterectomy for adenomyosis likely underestimates the prevalence as tissue may not have been routinely investigated for the condition. In addition, prevalence studies of uterine fibroids and adenomyosis all recruited multiparous women in their fourth and fifth decades of life, making comparison of estimates with global figures difficult. The lack of well-conducted, population-based studies limits the understanding of the public health impact of these conditions and prioritize diagnostic and management pathways.

Limitations and Strengths
This is the first systematic review of the prevalence of common gynecological conditions in Middle Eastern women. Study and reporting quality were generally low; however, the moderate/high heterogeneity that were present in the pooled data was reduced after completing subgroup analysis using relevant variables to limit bias. Potential explanations of residual heterogeneity among the studies are likely due to differences in study populations, sampling schemes, and study designs (case definition and ascertainment). Most of the studies selected women through convenience sampling, from hospitals, which may either overestimate the prevalence of the diseases or underestimate the disease risk due to missed asymptomatic cases. Prevalence estimates from retrospectively screened medical records are potentially affected by selection and information biases, as well as methodological issues, such as a lack of specific inclusion and exclusion criteria and data abstraction protocols. Beyond the limitations of the existing literature, there are fundamental issues with the diagnostic method used for the gynecological conditions, which hinders derivation of true population prevalence. The heterogeneous nature of PCOS in terms of its definition, diagnostic criteria, and ethnic variability likely leads to variable PCOS prevalence estimates in different populations. The lack of a non-invasive diagnostic modality for endometriosis creates diagnostic bias for those that are unable to access surgical evaluation. In addition, much of the information available on uterine fibroids and adenomyosis prevalence came from hospital-based studies that lacked imaging and symptomatology-based diagnosis and were not representative of the general population.

Social and cultural factors play a role in diagnostic bias. Given that women in the region will more likely consult a physician for fertility-related issues, as opposed to pain or menstrual irregularities (61), the studies conducted in a hospital-based setting are based on highly selected populations that cannot be generalized broadly. In addition, gynecological conditions and associated clinical phenotypes may present differently in various populations. Given the lack of epidemiological studies in the region focusing on symptomatology and phenotypes, the standard clinical definitions based on mainly Western population health data may not adequately capture the symptom presence and severity affecting diagnostic pathways of these heterogeneous conditions (134, 135). In fact, treatment regimens and responses vary widely between regions and among ethnic groups (136).

There is an underrepresentation of studies from low- and middle-income regions in the Middle East that have been subject to war and political instability (Iraq, Syria, Libya, Sudan, Lebanon, Yemen, and Palestine), as opposed to higher-income regions, such as the Gulf countries, Turkey, and Egypt, where women have greater access to health care and may be more intensively screened.
This review highlights the importance of investigating gynecological health in the Middle East, and the need for well-designed studies that address both prevalence and the impact of gynecological condition on women’s lives. An extensive search was conducted in two languages, to avoid missing any relevant information. We performed a broad search, including manuscripts from gray literature. Potential sources of bias were identified, and significant clinical and statistical heterogeneity was discussed to indicate considerable variability in the data due to residual confounding and study design. It is essential to prioritize improved and unbiased quantification of gynecological condition prevalence and incidence extrapolation, to improve generalizability and improve public health focus.

Further epidemiological studies must be conducted to investigate symptomatology and risk factors in women of this region, to deliver more culturally sensitive healthcare (137). Specific areas in need of attention include improving the clinical definition, diagnostic techniques, and treatment methods to provide the best practice for this diverse patient population. More generally, given the potential effects of these common chronic conditions on personal lives, economies, healthcare systems, and global community, it must be a public health priority to advance our understanding of the complex pathways leading to diagnosis, develop targeted prevention, and provide early detection guidelines in different populations (138–143). Key to this endeavor is advancing our understanding of how genetic and non-genetic factors interplay to disease predisposition and mechanisms in different populations (144).

CONCLUSION

To our knowledge, this is the first systematic review study to investigate the prevalence of common gynecological diseases in women in Middle Eastern populations, highlighting a paucity in reliable data. With 200 million women in the region, the importance of conducting more research in the area of women's health is clear and is needed to serve as a benchmark for evaluation of future research activities and comparative purposes with Middle Eastern immigrants and other populations. A gynecology clinic in the Middle East remains the realm mostly of married women. Young women may suffer from chronic pain and menstrual irregularities, but the hegemony of traditions may prevent them from discussing these and thus prolong suffering. To continue to decrease health disparities, researchers should acknowledge the limitations in scientific research that investigate the health disparities in women of Middle Eastern region. Robust data will urge policymakers in the Middle East to invest in health information systems to better identify risk factors for gynecological diseases, help set targets for policymaking, impact public awareness, and enable educational and evaluation strategies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

MM and NR were involved in all parts of the study: conception, study design, acquisition of data, information extraction, quality assessment, analysis, meta-analysis plots, interpretation, drafting of manuscript, and final approval. KZ and CB were responsible for conception, study design, analysis methods, interpretation, drafting of manuscript, and final approval. SK identified the search terms, developed the search strategies, conducted the search on each database to find relevant studies, reviewed the literature search method section of the manuscript, and did the final approval. MA-J, HA, CL, and SM were involved in study design, interpretation, reviewing of the manuscript, and final approval. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/frph.2021.661360/full#supplementary-material

REFERENCES

1. Azziz R. Adenomyosis: current perspectives. Obstet Gynecol Clin North Am. (1989) 16:221–35.
2. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Prim. (2016) 2:16057. doi: 10.1038/nrdp.2016.57
3. Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nat Rev Dis Prim. (2016) 2:16043. doi: 10.1038/nrdp.2016.43
4. Zondervan KT, Becker CM, Koga K, Meeusen S, Mayer BK, Vignan P. Endometriosis. Nat Rev Dis Prim. (2018) 4:9. doi: 10.1038/s41572-018-0008-5
5. Lizeva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. (2016) 106:6–15. doi: 10.1016/j.fertnstert.2016.05.003
6. Yıldız BO, Bozdag G, Yapici Z, Esiner I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. (2012) 27:3067–73. doi: 10.1093/humrep/dex232
7. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yıldız BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. (2016) 31:1–15. doi: 10.1093/humrep/dew218
8. Dewailly D, Hieronimus S, Mirakian P, Hunger J-N. Polycystic ovary syndrome (PCOS). Ann Endocrinol. (2010) 71:8–13. doi: 10.1016/j.ando.2009.12.003
9. Dumesci DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. (2015) 36:487–525. doi: 10.1210/er.2015-1018
10. Yen SSC, Jaffe RB. Yen and Jaffe’s Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Philadelphia, PA: Elsevier Health Sciences (2009).
11. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life Span. J Clin Endocrinol Metab. (2005) 90:4650–8. doi: 10.1210/jc.2005-0628

12. Jason J. Polycystic ovary syndrome in the united states: clinical visit rates, characteristics, and associated health care costs. Arch Intern Med. (2011) 171:1209. doi: 10.1001/archinternmed.2011.288

13. Duignan NM, Jordan JA, Coughlan BM, Logan-Edwards R. One thousand consecutive cases of diagnostic laparoscopy. BJOG An Int J Obstet Gynaecol. (1972) 79:1016–24. doi: 10.1111/1471-0528.1972.tb11880.x

14. Giudice LC. Endometriosis. N Engl J Med. (2010) 362:2389–98. doi: 10.1056/NEJMcp1000274

15. Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. (2009) 92:68–74. doi: 10.1016/j.fertnstert.2008.04.056

16. Missmer SA, Cramer DW. The epidemiology of endometriosis. Obstet Gynecol Clin North Am. (2003) 30:1–19. doi: 10.1016/S0889-8545(02)00050-5

17. Shafrir AL, Farland LV, Shah DK, Harris HR, Kvasnok M, Zondervan K, et al. Risk for and consequences of endometriosis: a critical epidemiologic review. Best Pract Res Clin Obstet Gynaecol. (2018) 51:115–5. doi: 10.1016/j.bpbogn.2018.06.001

18. Prescott J, Farland LV, Tobias DK, Gaskins AJ, Spiegelman D, Chavarro JE, et al. A prospective cohort study of endometriosis and subsequent risk of infertility. Hum Reprod. (2016) 31:1475–82. doi: 10.1093/humrep/dev085

19. Shah DK, Correia KE, Vitonis AF, Missmer SA. Body size and endometriosis: results from 20 years of follow-up within the Nurses’ Health Study II prospective cohort. Hum Reprod. (2013) 28:1783–92. doi: 10.1093/humrep/det120

20. Simoes S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod. (2012) 27:1292–9. doi: 10.1093/humrep/deq073

21. Vercellini P, Viganò P, Somigliana E, Daguati R, Abbiati A, Fedele L. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. (2006) 20:465–77. doi: 10.1016/j.bpbogn.2006.01.017

22. Ferencycz A. Pathophysiology of adenomyosis. Hum Reprod Update. (1998) 4:312–22. doi: 10.1093/humupd/d4.3.312

23. Vercellini P, Chatenoud L, Panazza S, Parazzini F, Crosignani PG, Oldani S. Risk factors for adenomyosis. Hum Reprod. (2002) 12:1275–9. doi: 10.1093/humrep/12.6.1275

24. Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod Update. (1998) 4:323–36.

25. Liu XF, Huang LH, Zhang C, Huang GH, Yan LM, He J. A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study. BJOG An Int J Obstet Gynaecol. (2017) 124:40–5. doi: 10.1111/1471-0528.14746

26. Parazzini F, Negri E, La Vecchia C, Somigliana E, Daguati R, Abbiati A, Fedele L. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. (2006) 20:465–77. doi: 10.1016/j.bpbogn.2006.01.017

27. Lee DW, Carls GS, Stewart E, Gibson TB, Ozminkowski RJ, Wang S. What are the total costs of surgical treatment for uterine fibroids? J Women’s Heal. (2008) 17:1119–32. doi: 10.1089/jwh.2008.0456

28. World Population Prospects. Available online at: http://www.un.org/en/development/esa/population/

29. Habibzadeh F. Geopolitical changes and trends in middle eastern countries’ contributions to world science over the past three decades. Arch Iran Med. (2011) 14:310–1.

30. Batniji R, Khatib L, Cammett M, Sweet J, Basu S, Jamal A, et al. Health in the Arab world: a view from within I: governance and health in the Arab world. Lancet. (2014) 383:343–55. doi: 10.1016/S0140-6736(13)62820-2

31. Moe SA, Hassan A, Aql M, Usmani AM. Medical education research in GCC countries. BMC Med Educ. (2015) 15:8. doi: 10.1186/s12909-015-0293-6

32. Rouidi-Fahimi F. Women’s reproductive health in the Middle East and North Africa. Popul Ref. Bar. (2003) 1:4–7.
Mousa et al. Prevalence of Gynecological Conditions in the Middle East

18

April 2021 | Volume 3 | Article 661360

Prevalence and Incidence of Uterine Fibroid at King Abdulaziz University Hospital; a teaching hospital experience. *Brunei Int Med J.* (2011) 64:380–2. doi: 10.1016/j.jclinepi.2010.09.011

Ragab A, Shams M, Badawy A, Alsamamia MA, Ragab A. Prevalence of endometriosis among adolescent school girls with severe dysmenorrhea: a cross sectional prospective study. *Int J Health Sci.* (2015) 9:273–81. doi: 10.12816/0024694

Saleh HA, Shawky Mostafa FM. Polycystic ovarian syndrome and congenital uterine anomalies: the hidden common player. *Arch Gynecol Obstet.* (2014) 290:355–60. doi: 10.1007/s00404-014-3193-9

Sanad AS. Prevalence of polycystic ovary syndrome among fertile and infertile women in Minia Governorate, Egypt. *Int J Gynecol Obstet.* (2014) 125:81–2. doi: 10.1016/j.ijgo.2013.09.025

Siam S. Gynecologic laparoscopy and reproductive failure: review of 4103 infertile women. *Middle East Fertil Soc J.* (2006) 11:196–201.

Ragab A, Shams M, Badawy A, Alsamamia MA, Ragab A. Prevalence of endometriosis among adolescent school girls with severe dysmenorrhea: a cross sectional prospective study. *Int J Health Sci.* (2015) 9:273–81. doi: 10.12816/0024694

Aliani F, Ashrafi M, Arabipoor A, Shahrokh-Tehraninejad E, Jahanian Sadatmahalleh S, Akhond MR. Comparison of the symptoms and presentation and etiologic factors of hirsutism in premenopausal Iranian women. *Middle East Fertil Soc J.* (2011) 4:156–9.

Ashrafi M, Jahanian Sadatmahalleh S, Akhond MR, Talebi M. Evaluation of risk factors associated with endometriosis in infertile women. *Int J Fertil Steril.* (2010) 4:122–7. doi: 10.1186/1757-2215-4-122

Zreik RS, Nasrallah MP. The prevalence of endocrinopathies among Lebanese women presenting with hirsutism to an endocrine clinic. *J Med Liban.* (2014) 62:27–32. doi: 10.12816/0002624

Eggert J, Li X, Sundquist K. Country of birth and hospitalization for pelvic inflammatory disease, ectopic pregnancy, endometriosis, and infertility: a nationwide study of 2 million women in Sweden. *Fertil Steril.* (2008) 90:1019–23. doi: 10.1016/j.fertnstert.2007.12.045

Al Khudiri M, Al Farwani Y, Al Najjar TAA, Gowi V. Hospital-based prevalence of polycystic ovarian syndrome among Omani women. *Middle East Fertil Soc J.* (2014) 19:135–8. doi: 10.1016/j.medfes.2013.06.006

Varghese U, Varughese S. Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman. *Brunei Int Med J.* (2012) 8:248–52.

Musmar S, Afaneh A, Mo’alla H. Epidemiology of polycystic ovary syndrome: a cross sectional study of University students at An-Najah national University-Palestine. *Reprod Biol Endocrinol.* (2013) 11:1.

doi: 10.1186/1477-7827-11-47

Dargham SR, Ahmed L, Kilpatrick ES, Atkin SL. The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. *PLoS ONE.* (2017) 12:e0181467. doi: 10.1371/journal.pone.0181467

Sharif E, Rahman S, Zia Y, Rizk NM. The frequency of polycystic ovarian syndrome in young reproductive females in Qatar. *Int J Womens Health.* (2017) 9:1–10. doi: 10.2147/IJWH.S120027

Abbas HY, Awad IA, Alharbi E, Alaaemery H, Alhubaiti S, Ashkar L. Prevalence and Incidence of Uterine Fibroid at King Abdulaziz University Hospital Saudi Arabia. *Clin Med Diagnostics.* (2016) 6:45–8. doi: 10.5923/j.cmed.20160603.01

Al-Kadri HM, Al-Turki HA, Saleh AM. Short and long term complications of abdominal and vaginal hysterectomy for benign disease. *Saudi Med J.* (2002) 23:806–10.
137. Hammoud MM, White CB, Fetters MD. Opening cultural doors: providing culturally sensitive healthcare to Arab American and American Muslim patients. *Am J Obstet Gynecol.* (2005) 193:1307–11. doi: 10.1016/j.ajog.2005.06.065

138. Smith GD, Chaturvedi N, Harding S, Nazroo J, Williams R. Ethnic inequalities in health: a review of UK epidemiological evidence. *Crit Public Health.* (2000) 10:375–408. doi: 10.1080/0958159010005331

139. Defong J, Jawad R, Mortagy I, Shepard B. The sexual and reproductive health of young people in the Arab countries and Iran. *Reprod Health Matters.* (2005) 13:49–59. doi: 10.1016/S0968-8080(05)25181-9

140. World Health Organization. *Cross-Cutting Gender Issues in Women's Health in the Eastern Mediterranean Region* (2007).

141. Williams DR, Mohammed SA, Leavell J, Collins C. Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities. *Ann N Y Acad Sci.* (2010) 1186:69–101. doi: 10.1111/j.1749-6632.2009.05339.x

142. Davidson PM, McGrath SJ, Meleis AI, Stern P, DiGiacomo M, Dharmendra T, et al. The health of women and girls determines the health and well-being of our modern world: a white paper from the international council on women’s health issues. *Health Care Women Int.* (2011). doi: 10.1080/07399332.2011.603872

143. Lawrence DS, Hirsch LA. Decolonising global health: transnational research partnerships under the spotlight. *Int Health.* (2020) 12:518–23. doi: 10.1093/inthealth/ihaa073

144. Olden K, Freudenberg N, Dowd J, Shields AE. Discovering how environmental exposures alter genes could lead to new treatments for chronic illnesses. *Health Aff.* (2011) 30:833–41. doi: 10.1377/hlthaff.2011.0078

**Conflict of Interest:** SM has been a member of advisory/scientific boards for AbbVie. CB reports grant from Bayer AG, others from AbbVie Inc., grants from Voleon Rx, grants from MDNA Life Sciences, grants from Roche Diagnostics Inc., nonfinancial support from Population Diagnostics Ltd, others from ObsEva, and others from Flo Health, outside the submitted work. KZ reports grants from Bayer Healthcare, MDNA Life Sciences, Roche Diagnostics Inc., Voleon Rx, and Evotec (Lab282 - Partnership program with Oxford University), nonfinancial support from AbbVie Ltd, all outside the submitted work, and is a Board member (Secretary) of the World Endometriosis Society and World Endometriosis Research Foundation.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mousa, Al-Jefout, Alsafar, Kirtley, Lindgren, Missmer, Becker, Zondervan and Rahmioglu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.